earnings
confidence high
sentiment positive
materiality 0.75
Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance
GILEAD SCIENCES, INC.
2022-Q2 EPS reported
$0.92
revenue$12,850,000,000
- Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).
- Biktarvy sales $2.6B (+28% YoY); oncology sales $527M (+71% YoY) driven by cell therapy and Trodelvy.
- HIV product sales $4.2B (+7% YoY); HCV sales $448M (-18% YoY); Veklury sales $445M (-46% YoY).
- FY guidance raised: product sales $24.5-25.0B (prev $23.8-24.3B); non-GAAP EPS $6.35-6.75 (prev $6.20-6.70).
- Operating cash flow $1.8B in Q2; cash & equivalents $7.0B as of June 30, 2022.